ArticleDiabetology & metabolic syndrome2015

Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.

Yun-Zhao Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.